CMTx Biotech, Inc.
CMTx Biotech, Inc. is an emerging biopharmaceutical company working to develop and commercialize host-directed therapeutics for the treatment of inflammatory and infectious diseases, as well as threat-agnostic medical countermeasures against high-priority chemical, biological, radiological and nuclear (CBRN) threats to homeland security and national defense. Our lead drug candidate is a clinically-tested, highly-stable, orally-administered small molecule that has been shown to improve survival and prevent lung injury in a wide variety of animal models of sepsis, acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) across several species, including mice, rats, hamsters, pigs and sheep. Having already secured approximately $4M in funding to-date, including $3.6M in NIH SBIR/STTR grants, we are actively seeking non-dilutive funding, private investment capital and/or an established strategic partner to help advance human clinical trials and FDA Animal Rule development, as well as to expand our product pipeline.
CMTx Biotech, Inc.
Long Island High Technology Incubator (LIHTI), 25 Health Sciences Drive, Suite 314, Stony Brook, NY 11790-3350
CMTx Biotech, Inc. is currently seeking investment
CMTx Biotech, Inc. is seeking a seed investment in the range of 1m-5m
What We Do
CMTx Biotech is working to develop and commercialize a pipeline of host-directed therapeutics for the treatment of inflammatory and infectious diseases, as well as threat-agnostic medical countermeasures against high-priority chemical, biological, radiological and nuclear (CBRN) threats to homeland security and national defense. Host directed therapeutics are a promising class of treatments that target the hyperinflammatory and dysregulated immune response to infection or injury. Host directed therapeutics aim to improve survival, reduce morbidity, and resolve inflammation to protect against tissue and organ damage. Moreover, these treatments can be adjunctive to traditional antibiotic and anti-viral approaches, and represent an innovative solution in response to high-priority CBRN threats.
Incyclinide (CMT-3 / COL-3)
Our lead drug candidate is incyclinide, a clinically-tested, orally-administered, highly-stable small molecule drug candidate that is well-positioned for rapid development as a host-directed therapeutic and threat-agnostic medical countermeasure. Incyclinide was originally invented at Stony Brook University by our scientific co-founder, Dr. Larry Golub, and further developed by the National Cancer Institute and CollaGenex Pharmaceuticals, which had invested at least $17M in the program before being acquired by Galderma Corporation. Incyclinide has been the subject of several INDs and advanced into multiple human clinical trials, where it was shown to be well tolerated in over 450 patients for up to 150 weeks. Having previously been produced at scale under good manufacturing practices, the chemistry, manufacturing and controls for incyclinide are well-established. Importantly, as a clinical-stage new chemical entity, incyclinide is eligible for five years of market exclusivity upon a first approval for human use by the FDA.